Product Information
LEVALBUTEROL TAR HFA 45 MCG INH is a generic product labeled by Actavis Pharma, Inc., priced at $3.5497 per GM under NDC 00591292754. Its NADAC has been published 498 times since Mar 22, 2017.
FDA first approved this application on Mar 11, 2005.
Strength
45 ug/1
Manufacturer
Actavis Pharma, Inc.NDC
00591292754
Classification
Generic
Dosage Form
AEROSOL, METERED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVALBUTEROL TARTRATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA021730FDA Approved
3/11/2005
On Market Since
10/3/2016
Pharmacological Classes
Price Statistics
The NADAC for LEVALBUTEROL TAR HFA 45 MCG INH has been published 498 times since Mar 22, 2017, and over the history we have for it it has declined 5.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.5497 per GM |
|---|---|
| All-time high | $3.8714 (May 15, 2019) |
| All-time low | $3.1073 (Nov 20, 2024) |
| 52-week high | $3.5497 |
| 52-week low | $3.3129 |
| Median price | $3.6895 |
| Average price | $3.6445 |
| Largest weekly change | -13.8% (Nov 20, 2024) |
| Weeks tracked | 498 |
| Tracking since | Mar 22, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Actavis Pharma, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
levalbuterol tartrate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
beta2-Adrenergic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVALBUTEROL TAR HFA 45 MCG INH?
The current National Average Drug Acquisition Cost (NADAC) for LEVALBUTEROL TAR HFA 45 MCG INH, manufactured by Actavis Pharma, Inc., is $3.5497 per GM (NDC 00591292754), effective Sep 30, 2026.
How has the price of LEVALBUTEROL TAR HFA 45 MCG INH changed over time?
Over the history we have for it, the NADAC for LEVALBUTEROL TAR HFA 45 MCG INH has declined 5.4%. It has been tracked across 498 weekly CMS publications since Mar 22, 2017.
What are the highest and lowest recorded NADAC prices for LEVALBUTEROL TAR HFA 45 MCG INH?
Since Mar 22, 2017, the NADAC for LEVALBUTEROL TAR HFA 45 MCG INH has ranged from a low of $3.1073 (Nov 20, 2024) to a high of $3.8714 (May 15, 2019), with a median of $3.6895 per GM.
Are there cheaper alternatives to LEVALBUTEROL TAR HFA 45 MCG INH?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as LEVALBUTEROL TAR HFA 45 MCG INH in a comparable dosage form, but none are currently priced below it.
Who manufactures LEVALBUTEROL TAR HFA 45 MCG INH?
LEVALBUTEROL TAR HFA 45 MCG INH (NDC 00591292754) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.